Chardan Downgrades Outlook Therapeutics to Neutral From Buy, Puts Price Target 'Under Review' After $53 Price Target
Chardan Downgrades Outlook Therapeutics to Neutral From Buy, Puts Price Target 'Under Review' After $53 Price Target
Chardan将outlook therapeutics的评级从买入下调至中立，并在53美元的目标价格后将目标价格列为“待审查”。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间